Pharmacokinetics of oseltamivir in breast milk and maternal plasma

American Journal of Obstetrics and Gynecology

Volumn 204, Issue 6, 2011, Pages 524.e1-524.e4

  Greer, Laura G ^a   Leff, Richard D ^c   Rogers, Vanessa Laibl ^a   Roberts, Scott W ^a   McCracken Jr , George H ^a,b   Wendel Jr , George D ^a   Sheffield, Jeanne S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

breast milk pharmacokinetics; oseltamivir; oseltamivir excretion

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST MILK; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; FEMALE; HUMAN; INFLUENZA; MATERNAL PLASMA; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79958117181     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2011.01.056     Document Type: Article

References (19)

1. D.J. Jamieson, M.A. Honein, and S.A. Rasmussen H1N1 2009 influenza virus infection during pregnancy in the USA Lancet 374 2009 451 458
2. S.A. Rasmussen, D.J. Jamieson, K. MacFarlane, J.D. Cragan, J. Williams, and Z. Henderson Pandemic influenza and pregnant women: summary of a meeting of experts Am J Public Health 99 Suppl 2 2009 248 253
3. S. Hewagama, S.P. Walker, and R.L. Stuart 2009 H1N1 influenza A and pregnancy outcomes in Victoria, Australia Clin Infect Dis 50 2010 686 690
4. J.K. Louie, M. Acosta, D.J. Jamieson, and M. Honein Severe 2009 H1N1 influenza in pregnant and postpartum women in California N Engl J Med 362 2010 27 35
5. B.N. Archer, C. Cohen, and D. Naidoo Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases Euro Surveill 14 2009 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19369 Accessed Oct. 1, 2010
6. J.K. Louie, M. Acosta, and K. Winter Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California JAMA 302 2009 1896 1902
7. A.M. Siston, S.A. Rasmussen, and M.A. Honein Pandemic 2009 influenza A (H1N1) virus illness amount pregnant women in the United States JAMA 303 2010 1517 1525
8. A.A. Creanga, T.F. Johnson, S.B. Graitcer, L.K. Hartman, T. Al-Samarrai, and A.G. Schwarz Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women Obstet Gynecol 115 2010 717 726
9. A.C. Miller, F. Safi, S. Hussain, R.A. Subramanian, E.M. Elamin, and R. Sinert Novel influenza A (H1N1) virus among gravid admissions Arch Intern Med 170 2010 10868 10873
10. Centers for Disease Control and Prevention 2009 Pandemic influenza A (H1N1) in pregnant women requiring intensive careNew York City, 2009 MMWR Morb Mortal Wkly Rep 59 2010 321 325
11. Centers for Disease Control and Prevention Updated interim recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season http://www.cdc.gov/h1n1flu/pregnancy/antiviral-messages.htm Accessed June 4, 2010
12. M. Brewster, J.R. Smith, R. Dutkowski, and R. Robson Active metabolite from Tamiflu® solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomized, open-label study Vaccine 24 2006 6660 6663 (Pubitemid 46110796)
13. J.J. Shentag, G. Hill, T. Chu, and C.R. Rayner Similarity in pharmacokietnics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects J Clin Pharmacol 47 2007 689 696 (Pubitemid 46800424)
14. G. He, J. Massarell, and P. Ward Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolie Ro 64-0802 Clin Pharmacokinet 37 1999 471 484 (Pubitemid 30032251)
15. J.W. Massarella, G.Z. He, A. Dorr, K. Neiforth, P. Ward, and A. Brown The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers J Clin Pharmacol 40 2000 836 843
16. B.E. Davies Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations J Antimicrob Chemother 65 Suppl 2 2010 ii5 ii10
17. N. Wentges-Van Holthe, M. van Eijkeren, and J.W. van der Laan Oseltamivir and breastfeeding Int J Infect Dis 12 2008 451
18. D.W. Kimberlin, M. Shalabi, and M.J. Abzug Safety of oseltamivir compared with the adamantanes in children less than 12 months of age Pediatr Infect Dis J 29 2010 195 198
19. F.H.-L. Roche Tamiflu oseltamivir phosphate: product information, 2004 http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM183850.pdf Accessed May 1, 2010